This EBMT activity survey presents the status of hematopoietic stem cell transplantation (HSCT) in Europe 2003 and focuses on changes in stem cell source over the last decade. There were 21 028 first HSCT, 7091 allogeneic (34%), 13 937 autologous (66%) and 4179 additional re-or multiple transplants reported from 597 centers in 42 European countries in the year 2003. Main indications were leukemias (6613 (31%; 78% allogeneic)); lymphomas (11 571 (55%; 93% autologous)); solid tumors (1792 (9%; 92% autologous)) and nonmalignant disorders (898 (5%; 93% allogeneic)). In 1991, the vast majority of autologous and all allogeneic HSCT were still bone marrow (BM) transplants. Stem cell source changed rapidly to peripheral blood (PB) for autologous HSCT between 1992 and 1996. In 2003, 97% of autologous HSCT were PB derived. The change to PB for allogeneic HSCT followed 3 years later and occurred at a lower rate. In 2003, 65% of all allogeneic HSCT were PB derived. The change in stem cell source was not homogeneous. It was associated with donor type, main diagnosis, disease stage and it differed between European countries. In 2003, bone marrow remains a significant source of stem cells in some European countries for autologous HSCT and for nonmalignant disorders in allogeneic HSCT. Bone Marrow Transplantation (2005) 36, 575-590.
Summary:
This EBMT activity survey presents the status of hematopoietic stem cell transplantation (HSCT) in Europe 2003 and focuses on changes in stem cell source over the last decade. There were 21 028 first HSCT, 7091 allogeneic (34%), 13 937 autologous (66%) and 4179 additional re-or multiple transplants reported from 597 centers in 42 European countries in the year 2003. Main indications were leukemias (6613 (31%; 78% allogeneic)); lymphomas (11 571 (55%; 93% autologous)); solid tumors (1792 (9%; 92% autologous)) and nonmalignant disorders (898 (5%; 93% allogeneic)). In 1991, the vast majority of autologous and all allogeneic HSCT were still bone marrow (BM) transplants. Stem cell source changed rapidly to peripheral blood (PB) for autologous HSCT between 1992 and 1996. In 2003, 97% of autologous HSCT were PB derived. The change to PB for allogeneic HSCT followed 3 years later and occurred at a lower rate. In 2003, 65% of all allogeneic HSCT were PB derived. The change in stem cell source was not homogeneous. It was associated with donor type, main diagnosis, disease stage and it differed between European countries. In 2003, bone marrow remains a significant source of stem cells in some European countries for autologous HSCT and for nonmalignant disorders in allogeneic HSCT. Bone Marrow Transplantation (2005) 36, 575-590. doi:10.1038/sj.bmt.1705104; published online 8 August 2005 Keywords: hematopoietic stem cell; stem cell source; peripheral blood transplants; cord blood transplants Bone marrow was the primary source of stem cells for hematopoietic stem cell transplantation (HSCT) from the earliest days. Bone marrow harvesting was adequate for the collection of sufficient quantities of stem cells for durable engraftment in the majority of patients. [1] [2] [3] [4] Bone marrow transplantation remained the sole form of HSCT for many decades even after it became known that hematopoietic stem cells were present in the peripheral blood. In vitro studies and animal experiments had shown that circulating peripheral blood stem cells were capable of fully repopulating a hematopoietic system. [5] [6] [7] [8] Peripheral blood was not used clinically for two main reasons. The numbers of circulating stem cells were thought to be too low to be collected with reasonable methods for autologous and allogeneic HSCT. The numbers of contaminating T cells were considered too high for a safe allogeneic transplant. This fear was based on experience with donor buffy coat cells in the context of HSCT for severe aplastic anemia during the 1980s. The high rejection rate of bone marrow transplants in sensitized patients was successfully reduced by the addition of buffy coat cells from the bone marrow donor. The majority of these patients did engraft but suffered from severe chronic graft-versus-host disease (GVHD). Their survival was not improved and use of donor buffy coat cells was abandoned. [9] [10] [11] The change to peripheral blood as stem cell source came about by the parallel observation of several phenomena. Patients with chronic myeloid leukemia present with high numbers of circulating stem cells. Cells collected with one or two aphereses at the time of diagnosis proved to be sufficient to restore hematopoiesis to chronic phase in patients with transformed chronic myeloid leukemia when they were given after high-dose chemotherapy and/or total body irradiation. 12, 13 In vitro studies revealed that patients with lymphoma or solid tumors had high numbers of circulating stem cells as a rebound phenomenon after intensive chemotherapy.
14 Adequate numbers of stem cells could be collected for autologous transplantation during a well-defined time window. This rebound was accentuated by the addition of colony stimulating factors G-CSF or GM-CSF. 15 The potential of this powerful tool was quickly recognized and the combination of mobilization with growth factors after chemotherapy gained rapid acceptance. Prospective randomized studies confirmed the advantage of peripheral blood compared to bone marrow as a stem cell source. Today, peripheral blood is the main source 16, 17 of stem cells for autologous HSCT. 2, 18 The change in stem cell source to peripheral blood for allogeneic HSCT began later and proceeded more slowly. The first trials were triggered by the excellent results of peripheral blood HSCT in the autologous setting, by animal experiments and by preliminary case reports. 2, 17, 19 Case studies and cord blood transplants confirmed the potential of peripheral blood as full hematopoietic stem cell source. 20, 21 Safety with regard to the risk of acute and chronic GVHD remained of concern. The debate on differences in acute and chronic GVHD following either source of stem cells is still ongoing. Peripheral blood is today an accepted source for allogeneic HSCT but its final place in relation to bone marrow remains to be defined. [22] [23] [24] [25] [26] [27] [28] In this analysis, we used data from the EBMT activity surveys from the last 14 years.
29 By chance, the EBMT activity survey was introduced just at the onset of change in stem cell source. The comprehensive data give clear information about the change and the factors associated with this change. The survey covers the current status in Europe and provides information for transplant physicians and health care providers alike.
Patients and methods

Data collection and validation
Since 1990 all EBMT members and affiliated nonmembers have been asked annually to report on a survey sheet the numbers of new patients by indication, stem cell source and donor type. 29 Furthermore, the form collects generic information on the numbers of additional re-or multiple transplants, on the percentage of cord blood HSCT and, since 1999, on the percentage of transplants with reduced intensity conditioning (RIC) HSCT. Data are validated by the reporting team, which receives a computer printout of the entered data, and by cross checking with national registries. Teams are subjected to onsite visits.
The EBMT survey was adopted by the General Assembly as a mandatory self-reporting system. It now forms an integral part of a comprehensive quality assurance programme JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy ISCT and the European Group for Blood and Marrow Transplantation EBMT) (http://www.EBMT.org). 
Transplant rates
Transplant rates were defined as the number of HSCT per 10 million inhabitants. They were computed by disease indication and donor type for each country, as previously defined. Transplant rates were assessed for all HSCT and separately for autologous, allogeneic and unrelated HSCT. They were also assessed for RIC allogeneic HSCT, DLI and cord blood HSCT. 33 Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross national borders and receive their HSCT in a foreign country.
In addition to absolute transplant rates, the proportion of patients transplanted with bone marrow or peripheral blood was calculated according to disease and main disease category. Population data were obtained from the US census office (http://www.census.gov).
Statistical analysis
Different statistical methods were used to analyze the data. Mean, median and standard deviations of numerical variables were calculated on an Excel spreadsheet. The shift from bone marrow to peripheral blood as the stem cell source was analyzed with descriptive statistical analysis.
Shift was considered as the diffusion of a technology and described as such.
Results
Participating teams
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Numbers of HSCT in 2003
Stem cell source
Of the 13 937 autologous first transplants, 364 (3%) were bone marrow derived, 13 573 (97%) from peripheral blood stem cells or from combined bone marrow and peripheral blood (137 patients) stem cell transplants (Table 1) . Of the 7091 allogeneic first transplants, 35% were bone marrow and 65% were peripheral blood stem cell transplants. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 68% for HLA-identical sibling donor transplants, 78% for HSCT from other family members, 68% for twin donors and 58% for unrelated donors. Changes in stem cell source [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] . Information on stem cell source has been available since 1991. At that time a few peripheral blood autologous HSCT were performed but no allogeneic HSCT as yet. Within 6 years, absolute numbers of autologous peripheral blood HSCT increased from about 400 to more than 12 000 from 1997 on, while autologous bone marrow HSCT declined from near 2400 to less than 400. The proportion of autologous peripheral blood HSCT increased rapidly during the same time from 15% to 490% (Figure 2 ). Allogeneic peripheral blood HSCT was first reported in 1993. They continued to increase steadily to an absolute number of more than 4500 in 2003. Bone marrow transplants increased initially up to the year 1998 but in absolute numbers were still higher in 2003 (2479) than in 1991 (2175). The proportion of peripheral blood HSCT increased from o1% in 1993 to 65% in 2003 ( Figure 2 ).
The change in stem cell source varied for the different donor types for allogeneic HSCT. It was first and most used in twin and nonidentical family donors. Use of peripheral blood for unrelated donors began with a delay of almost 4 years and is still used 10% less than in HLA-identical sibling transplants.
The change in stem cell source differed between European countries. Diffusion of peripheral blood as stem cell source for autologous HSCT occurred earlier in Western than in Eastern European countries, at a higher initial speed and to a greater extent. Bone marrow remained a substantial source of stem cell for autologous HSCT in some European countries even in 2003 (Figure 3a) . The difference in diffusion of peripheral blood as stem cell source for allogeneic HSCT was less pronounced between Western and Eastern European countries, but there remained substantial differences in the proportion of bone marrow or peripheral blood as stem cell source between European countries (Figure 3b ).
The change in stem cell source differed for the main disease categories and for disease stage. The change to peripheral blood occurred earlier, and its use remains higher in autologous HSCT for lymphoproliferative disorders and solid tumors than for leukemias or nonmalignant diseases (Figure 4a ). For allogeneic HSCT, peripheral blood was applied earlier and was used to a greater extent for patients with lymphoproliferative disorders and solid tumors, its use was lowest for patients with nonmalignant disorders (Figure 4b ). There was no difference in use of peripheral blood between severe aplastic anemia and other nonmalignant disorders. Within the disease categories, there was no difference in use of peripheral blood for patients with early disease (1st complete remission of acute leukemia or 1st chronic phase of chronic myeloid leukemia) compared to patients with advanced disease not in 1st remission or 1st chronic phase in autologous HSCT. This contrasts with allogeneic HSCT where patients with advanced disease were earlier and more frequently treated with peripheral blood as the stem cell source. 
Discussion
This review of transplant activity in Europe 2003 with emphasis on use of stem cell source shows some novel aspects on the use of bone marrow or peripheral blood and documents the current status of HSCT in Europe. HSCT remains an established therapy. 1, 2, 30 Allogeneic HSCT continue to increase at a rate of almost 10% per year, and autologous HSCT procedures maintain a plateau at the same level as last year. 35 There remain major differences in transplant rates between European countries which are in part explained by economic factors and differences in medical opinion, as reported earlier. 33, 35 This report shows some marked differences in the change from bone marrow to peripheral blood as the stem cell source. It cannot give explanations but the descriptive statistics can be used to generate some hypotheses.
The results of this survey document the almost complete shift from bone marrow to peripheral blood as stem cell source for autologous HSCT within a decade and clarify some of the factors associated with this change. Diffusion of this change in Europe was earlier and more rapid in Western than in Eastern Europe, and was earlier and more complete for lymphoproliferative disorders and for solid tumors, and was similar for patients with early or advanced disease stage. The rapid change and almost complete diffusion is no surprise. Early prospective randomized studies documented the clear advantage of peripheral blood as the stem cell source. 16, 17 There was a more rapid recovery with peripheral blood, a lower need for transfusions and antibiotics and a shorter hospital stay. There was no obvious disadvantage; the postulated higher contamination rate of peripheral blood with tumor cells was not confirmed.
36
However, bone marrow remains the source for HSCT in a substantial proportion of patients, mainly in Eastern European countries. Peripheral blood collection depends on an infrastructure with cell separators and growth factors. In countries where manpower is less costly than machines or drugs, bone marrow might appear more affordable than peripheral blood as stem cell source, even though cost effectiveness analyses in Western European countries showed a cost benefit advantage for peripheral blood.
37
The pattern is different for allogeneic HSCT. 38 Diffusion began later than for autologous HSCT, with less speed, similar in Eastern and Western Europe but with big differences between European countries and big differences with regard to donor type, disease and disease stage. In contrast to autologous HSCT, conclusions about advantage and disadvantage of peripheral blood compared to bone marrow are less clear. There is unequivocal evidence that engraftment is more rapid with peripheral blood. [22] [23] [24] [25] [26] [27] [28] This translates into an early survival advantage for patients with advanced disease. It is also becoming clear that peripheral blood is associated with an increased risk of acute and chronic GVHD. The final balance between the beneficial effect of graft-versus-leukemia effects and reduced relapse risk, and the detrimental effects of GVHD on transplant related mortality, still need to be defined. This dilemma is reflected by the data of this analysis. Use of peripheral blood is higher in patients with advanced leukemias compared to patients in 1st complete remission. Use of peripheral blood is also lower in patients with nonmalignant disorders, where conceivably no benefit can be derived from a graft-versus-host effect. Despite these considerations, the data show an increasing trend towards use of peripheral blood for nonmalignant disorders over the most recent years. Peripheral blood is also more frequently used for lymphoproliferative disorders and solid tumors; most likely this reflects the increasing use of RIC HSCT in these conditions. 39, 40 Risk of rejection has been reported to be lower with the use of peripheral blood in RIC HSCT.
41
In contrast to autologous HSCT, allogeneic HSCT procedures involve two individuals, the recipient and the donor. Concerns about the side effects of growth factors initially restricted the use of peripheral blood in unrelated donors; this is again reflected in this survey. Early data have confirmed the safety of both approaches for donors but have also clarified a different pattern of side effects. 25, 26, 42, 43 Bone marrow donation is mainly associated with side effects at the harvest site and anemia, peripheral blood donation mainly with side effects of the growth factors and the apheresis procedure. Fever and flu-like symptoms are frequent, mild side-effects of growth factor application, hypovolemia and hypocalcemia are frequent mild sideeffects of apheresis. Depending on their preferences donors might choose to have peripheral blood stem cell collection as an outpatient without the need for anesthesia or to have a rapid bone marrow collection without the need for growth factor administration. Both collection methods are associated with a low but not negligible risk of major complications and potentially death. Thromboembolic events have been reported after bone marrow harvest, vascular events and splenic rupture after peripheral blood donation. No difference in incidence of late malignancies has been observed so far for donors with either methods.
43
The rapid change of stem cell source reveals an additional problem. Current quality management guidelines for stem cell transplantation by the international organizations JACIE (www.EBMT.org) and FACT (www.FACT.org) require documentation of proficiency for stem cell collection. Teams performing mainly autologous HSCT or only lower numbers of allogeneic HSCT might soon lack the necessary expertise for bone marrow harvesting in those situations where it is actually needed. Novel concepts, such as teams covering bone marrow harvests for larger regions that might even cross national borders, are required. This will present a challenge to health care providers or insurance companies.
This EBMT activity survey gives no results on outcome. Such data are published elsewhere and with longer followup. Thanks to its rapid distribution, this survey describes current practice of HSCT in Europe and provides a basis for transplant specialists, health care administrators, patients and donors in their decision-making. 
